Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Trial of Neoadjuvant Immunotherapy (Atezolizumab) in Combination With CAPOX for Resectable Non-metastatic Proficient Mismatch Repair (pMMR) Colon CancER: NICER Study

NCT05870800 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT05870800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05870800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Trial of Neoadjuvant Immunotherapy (Atezolizumab) in Combination With CAPOX for Resectable Non-metastatic Proficient Mismatch Repair (pMMR) Colon CancER: NICER Study
Lead sponsor
Baylor College of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
June 15, 2025
Completion date
January 1, 2028
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage i colon cancer, stage ii colon cancer, stage iii colon cancer